Navigation Links
Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
Date:8/1/2013

luded at the end of this release are the reconciliations of adjusted financial results to the most closely applicable GAAP financial result.

Third party net revenues from Mylan's Generics segment, which are derived from sales in North America, Europe, the Middle East and Africa (collectively, EMEA) and Australia, India, Japan and New Zealand (collectively, Asia Pacific) were $1.45 billion in the quarter ended June 30, 2013, compared to $1.47 billion in the comparable prior year period, representing a decrease of $20.9 million. Excluding the unfavorable effect of foreign currency translation, Generics third party net revenues were essentially unchanged versus the comparable prior year period.

Third party net revenues from North America were $717.6 million for the current quarter, compared to $837.3 million for the comparable prior year period, representing a decrease of $119.7 million, or 14.3%. The decrease in third party net revenues was due to a greater amount of revenue from new product launches in the prior year ($240 million) as compared to the current year ($91 million), which was due principally to the launch of Escitalopram, our most significant product launch in the prior year. Excluding the impact of Escitalopram in both periods, third party net revenues in North America were essentially flat on a year-over-year basis. The effect of foreign currency translation was insignificant within North America.

Third party net revenues from EMEA were $375.5 million for the current quarter, compared to $326.6 million for the comparable prior year period, representing an increase of $48.8 million, or 14.9%. Foreign currency translation had a slightly favorable impact on sales for the current quarter, as translating current quarter third party net revenues from EMEA at prior year comparative period exchange rates resulted in an increase in third party net revenues of approximately 13%. This increase was principally the result of a double-digit
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
2. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
3. Roger Graham Named President of Mylan Specialty
4. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
5. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
6. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
7. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
8. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
9. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
10. Deborah Autor, FDAs Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
11. Mylan Announces $1 Million Gift to The Pittsburgh Promise Scholarship Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
(Date:12/24/2014)... Dec. 23, 2014   Assurex Health, a ... to healthcare providers for behavioral health and chronic ... $30 million in equity financing from new and ... , President and Chief Executive Officer. ... development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... Thousands of transvaginal mesh lawsuits ( ... number of multidistrict litigations currently underway in U.S. District ... reports. According to an Order issued on December 2, ... Status Conference in all of the proceedings on January ... to submit a proposed agenda to the Court by ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... sure they,ve made the right choice , ... ... annual Medicare enrollment has ended, some Medicare Advantage beneficiaries can ... period. That information comes from Allsup , a leading ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
... recall of King Nut brand after Minn. officials find bacteria ... been sickened , , SUNDAY, Jan. 11 (HealthDay News) -- ... for two brands of peanut butter after health officials in ... a tub of peanut butter that is distributed to schools ...
... giving guests a reason to be cheerful by announcing a winter sale ... ... (PRWEB) January 11, 2009 -- The Linwood Group has revealed that it ... can access its first rate facilities., , ,From Christmas through to the ...
... Ohio-based manufacturer and long-standing leader in the development of ergonomic ... with a solution to a unique furnishing challenge it faced ... ... Bowling Green, OH (PRWEB) January 10, 2009 ...
... The Asthma and Allergy Foundation of America (AAFA) announces ... been appointed to the Council of the National Institute ... the National Institutes of Health (NIH), for a four-year ... provides a diverse perspective on science, health and the ...
Cached Medicine News:Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 2Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 4Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 5Health News:Acclarent, Inc. Closes $26 Million Financing 2Health News:Peanut Butter Recalled as Salmonella Search Continues 2Health News:Peanut Butter Recalled as Salmonella Search Continues 3Health News:Peanut Butter Recalled as Salmonella Search Continues 4Health News:Linwood Group Setting Price Benchmark for Alcohol Rehab 2Health News:BioFit 1Y Takes the Plunge to Fill Undersea Seating Role for NOAA 2Health News:Asthma & Allergy Foundation CEO Appointed to NIH Council 2
Kit for the Preparation of Technetium Tc 99m Sestamibi for injection...
Straight Tip, Measures from 0mm to 20mm in 1mm Increments, Readable on Both Sides, Thumbscrew Lock Holds Desired Setting; in Titanium....
Very fine, blunt tip....
... The e.cam duet Signature Series ... and PET FDG imaging applications. The system ... capability with the features and flexibility of ... in one unit.,The e.cam duet ...
Medicine Products: